{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:33:48Z","timestamp":1794746028612,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8079","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,9,4]]},"DOI":"10.1038\/s41586-025-09265-8","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:03:21Z","timestamp":1753283001000},"page":"262-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction"],"prefix":"10.1038","volume":"645","author":[{"given":"Mathieu","family":"Oosterlaken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Rogliardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Lipina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-3102","authenticated-orcid":false,"given":"Pierre-Andr\u00e9","family":"Lafon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille Elodie","family":"Tsitokana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4717-3446","authenticated-orcid":false,"given":"Mathilde","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lo\u00efse","family":"Cahuzac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8778-9901","authenticated-orcid":false,"given":"Pierre","family":"Prieu-S\u00e9randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-8752","authenticated-orcid":false,"given":"S\u00e9verine","family":"Diem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2743-4023","authenticated-orcid":false,"given":"C\u00e9cile","family":"Derieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Camberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystel","family":"Lafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-6286","authenticated-orcid":false,"given":"Patrick","family":"Chames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-7037","authenticated-orcid":false,"given":"Franck","family":"Vandermoere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-7274","authenticated-orcid":false,"given":"Philippe","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-1084","authenticated-orcid":false,"given":"Laurent","family":"Pr\u00e9zeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-1691","authenticated-orcid":false,"given":"Denis","family":"Servent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salahpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2717-5279","authenticated-orcid":false,"given":"Amy J.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7385-681X","authenticated-orcid":false,"given":"Carine","family":"B\u00e9camel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-345X","authenticated-orcid":false,"given":"Jean-Philippe","family":"Pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-0999","authenticated-orcid":false,"given":"Julie","family":"Kniazeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2738","authenticated-orcid":false,"given":"Philippe","family":"Rondard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"9265_CR1","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1021\/acs.bioconjchem.8b00548","volume":"29","author":"NN Kumar","year":"2018","unstructured":"Kumar, N. N. et al. Passive immunotherapies for central nervous system disorders: current delivery challenges and new approaches. Bioconjug. Chem. 29, 3937\u20133966 (2018).","journal-title":"Bioconjug. Chem."},{"key":"9265_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen, G. C., Meyer, A. H., Bell, R. D. & Zhang, W. Strategies for delivering therapeutics across the blood-brain barrier. Nat. Rev. Drug. Discov. 20, 362\u2013383 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"9265_CR3","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/febs.15515","volume":"288","author":"S Muyldermans","year":"2021","unstructured":"Muyldermans, S. A guide to: generation and design of nanobodies. FEBS J. 288, 2084\u20132102 (2021).","journal-title":"FEBS J."},{"key":"9265_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"9265_CR5","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/S0140-6736(24)01883-X","volume":"404","author":"MT Heneka","year":"2024","unstructured":"Heneka, M. T., Morgan, D. & Jessen, F. Passive anti-amyloid \u03b2 immunotherapy in Alzheimer\u2019s disease-opportunities and challenges. Lancet 404, 2198\u20132208 (2024).","journal-title":"Lancet"},{"key":"9265_CR6","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1096\/fj.11-201384","volume":"26","author":"T Li","year":"2012","unstructured":"Li, T. et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 26, 3969\u20133979 (2012).","journal-title":"FASEB J."},{"key":"9265_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.09.019","volume":"243","author":"T Li","year":"2016","unstructured":"Li, T. et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J. Control. Release 243, 1\u201310 (2016).","journal-title":"J. Control. Release"},{"key":"9265_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1096\/fj.01-0343fje","volume":"16","author":"A Muruganandam","year":"2002","unstructured":"Muruganandam, A., Tanha, J., Narang, S. & Stanimirovic, D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16, 240\u2013242 (2002).","journal-title":"FASEB J."},{"key":"9265_CR9","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1111\/j.1476-5381.2011.01723.x","volume":"165","author":"G Caljon","year":"2012","unstructured":"Caljon, G. et al. Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier. Br. J. Pharmacol. 165, 2341\u20132353 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"9265_CR10","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.3390\/ijms24032632","volume":"24","author":"ME Tsitokana","year":"2023","unstructured":"Tsitokana, M. E., Lafon, P.-A., Pr\u00e9zeau, L., Pin, J.-P. & Rondard, P. Targeting the brain with single-domain antibodies: greater potential than stated so far? Int. J. Mol. Sci. 24, 2632 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"9265_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01489-1","volume":"8","author":"P Scholler","year":"2017","unstructured":"Scholler, P. et al. Allosteric nanobodies uncover a role of hippocampal mGlu2 receptor homodimers in contextual fear consolidation. Nat. Commun. 8, 1967 (2017).","journal-title":"Nat. Commun."},{"key":"9265_CR12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105848118","volume":"118","author":"J Haubrich","year":"2021","unstructured":"Haubrich, J. et al. A nanobody activating metabotropic glutamate receptor 4 discriminates between homo- and heterodimers. Proc. Natl Acad. Sci. USA 118, e2105848118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9265_CR13","doi-asserted-by":"publisher","first-page":"20284","DOI":"10.1073\/pnas.2009029117","volume":"117","author":"C McMahon","year":"2020","unstructured":"McMahon, C. et al. Synthetic nanobodies as angiotensin receptor blockers. Proc. Natl Acad. Sci. USA 117, 20284\u201320291 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9265_CR14","doi-asserted-by":"publisher","first-page":"20565","DOI":"10.1073\/pnas.1012865107","volume":"107","author":"S J\u00e4hnichen","year":"2010","unstructured":"J\u00e4hnichen, S. et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl Acad. Sci. USA 107, 20565\u201320570 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9265_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax7379","volume":"6","author":"Y Ma","year":"2020","unstructured":"Ma, Y. et al. Structure-guided discovery of a single-domain antibody agonist against human apelin receptor. Sci. Adv. 6, eaax7379 (2020).","journal-title":"Sci. Adv."},{"key":"9265_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.neuron.2018.05.018","volume":"98","author":"A Reiner","year":"2018","unstructured":"Reiner, A. & Levitz, J. Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert. Neuron 98, 1080\u20131098 (2018).","journal-title":"Neuron"},{"key":"9265_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tins.2015.06.002","volume":"38","author":"A Ellaithy","year":"2015","unstructured":"Ellaithy, A., Younkin, J., Gonz\u00e1lez-Maeso, J. & Logothetis, D. E. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends Neurosci. 38, 506\u2013516 (2015).","journal-title":"Trends Neurosci."},{"key":"9265_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/molpharm.121.000460","volume":"101","author":"S Dogra","year":"2022","unstructured":"Dogra, S. & Conn, P. J. Metabotropic glutamate receptors as emerging targets for the treatment of schizophrenia. Mol. Pharmacol. 101, 275\u2013285 (2022).","journal-title":"Mol. Pharmacol."},{"key":"9265_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"ST Patil","year":"2007","unstructured":"Patil, S. T. et al. Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 13, 1102\u20131107 (2007).","journal-title":"Nat. Med."},{"key":"9265_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-143","volume":"13","author":"DH Adams","year":"2013","unstructured":"Adams, D. H. et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry 13, 143 (2013).","journal-title":"BMC Psychiatry"},{"key":"9265_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","volume":"31","author":"BJ Kinon","year":"2011","unstructured":"Kinon, B. J. et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol. 31, 349\u2013355 (2011).","journal-title":"J. Clin. Psychopharmacol."},{"key":"9265_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","volume":"78","author":"BJ Kinon","year":"2015","unstructured":"Kinon, B. J., Millen, B. A., Zhang, L. & McKinzie, D. L. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol. Psychiatry 78, 754\u2013762 (2015).","journal-title":"Biol. Psychiatry"},{"key":"9265_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03495-2","volume":"594","author":"S Lin","year":"2021","unstructured":"Lin, S. et al. Structures of Gi-bound metabotropic glutamate receptors mGlu2 and mGlu4. Nature 594, 583\u2013588 (2021).","journal-title":"Nature"},{"key":"9265_CR24","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1248\/bpb.32.1576","volume":"32","author":"A Nakatani-Pawlak","year":"2009","unstructured":"Nakatani-Pawlak, A., Yamaguchi, K., Tatsumi, Y., Mizoguchi, H. & Yoneda, Y. Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood. Biol. Pharm. Bull. 32, 1576\u20131583 (2009).","journal-title":"Biol. Pharm. Bull."},{"key":"9265_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0079-6123(09)17906-2","volume":"179","author":"AJ Ramsey","year":"2009","unstructured":"Ramsey, A. J. NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia. Prog. Brain Res. 179, 51\u201358 (2009).","journal-title":"Prog. Brain Res."},{"key":"9265_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0092-8674(00)81972-8","volume":"98","author":"AR Mohn","year":"1999","unstructured":"Mohn, A. R., Gainetdinov, R. R., Caron, M. G. & Koller, B. H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427\u2013436 (1999).","journal-title":"Cell"},{"key":"9265_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuropharm.2012.01.019","volume":"66","author":"RA Wright","year":"2013","unstructured":"Wright, R. A. et al. CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H]LY459477 autoradiography. Neuropharmacology 66, 89\u201398 (2013).","journal-title":"Neuropharmacology"},{"key":"9265_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jov\u010devska","year":"2020","unstructured":"Jov\u010devska, I. & Muyldermans, S. The therapeutic potential of nanobodies. BioDrugs 34, 11\u201326 (2020).","journal-title":"BioDrugs"},{"key":"9265_CR29","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/sj.npp.1301536","volume":"33","author":"S Bickel","year":"2008","unstructured":"Bickel, S., Lipp, H.-P. & Umbricht, D. Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function. Neuropsychopharmacology 33, 1680\u20131689 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"9265_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.bbr.2004.01.008","volume":"153","author":"GE Duncan","year":"2004","unstructured":"Duncan, G. E. et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav. Brain Res. 153, 507\u2013519 (2004).","journal-title":"Behav. Brain Res."},{"key":"9265_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbr.2005.05.012","volume":"163","author":"RL Fradley","year":"2005","unstructured":"Fradley, R. L. et al. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 163, 257\u2013264 (2005).","journal-title":"Behav. Brain Res."},{"key":"9265_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41586-022-05161-7","volume":"609","author":"A Ilanges","year":"2022","unstructured":"Ilanges, A. et al. Brainstem ADCYAP1+ neurons control multiple aspects of sickness behaviour. Nature 609, 761\u2013771 (2022).","journal-title":"Nature"},{"key":"9265_CR33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41586-024-07314-2","volume":"629","author":"C Wei","year":"2024","unstructured":"Wei, C. et al. Brain endothelial GSDMD activation mediates inflammatory BBB breakdown. Nature 629, 893\u2013900 (2024).","journal-title":"Nature"},{"key":"9265_CR34","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-07-2384","volume":"7","author":"BM Tijink","year":"2008","unstructured":"Tijink, B. M. et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer Ther. 7, 2288\u20132297 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"9265_CR35","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/pharmaceutics12100937","volume":"12","author":"E Pothin","year":"2020","unstructured":"Pothin, E., Lesuisse, D. & Lafaye, P. Brain delivery of single-domain antibodies: a focus on VHH and VNAR. Pharmaceutics 12, 937 (2020).","journal-title":"Pharmaceutics"},{"key":"9265_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","volume":"317","author":"P Debie","year":"2020","unstructured":"Debie, P. et al. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours. J. Control. Release 317, 34\u201342 (2020).","journal-title":"J. Control. Release"},{"key":"9265_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.sbi.2020.01.003","volume":"60","author":"T Ucha\u0144ski","year":"2020","unstructured":"Ucha\u0144ski, T., Pardon, E. & Steyaert, J. Nanobodies to study protein conformational states. Curr. Opin. Struct. Biol. 60, 117\u2013123 (2020).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"9265_CR38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ijc.10212","volume":"98","author":"V Cortez-Retamozo","year":"2002","unstructured":"Cortez-Retamozo, V. et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer 98, 456\u2013462 (2002).","journal-title":"Int. J. Cancer"},{"key":"9265_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632687","volume":"12","author":"C Ackaert","year":"2021","unstructured":"Ackaert, C. et al. Immunogenicity risk profile of nanobodies. Front. Immunol. 12, 632687 (2021).","journal-title":"Front. Immunol."},{"key":"9265_CR40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nprot.2014.039","volume":"9","author":"E Pardon","year":"2014","unstructured":"Pardon, E. et al. A general protocol for the generation of nanobodies for structural biology. Nat. Protoc. 9, 674\u2013693 (2014).","journal-title":"Nat. Protoc."},{"key":"9265_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","volume":"172","author":"RE Litman","year":"2016","unstructured":"Litman, R. E. et al. AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study. Schizophr. Res. 172, 152\u2013157 (2016).","journal-title":"Schizophr. Res."},{"key":"9265_CR42","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/0269881115573403","volume":"29","author":"H Salih","year":"2015","unstructured":"Salih, H. et al. Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. J. Psychopharmacol. 29, 414\u2013425 (2015).","journal-title":"J. Psychopharmacol."},{"key":"9265_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/mol.114.094342","volume":"86","author":"A Christopoulos","year":"2014","unstructured":"Christopoulos, A. Advances in G protein-coupled receptor allostery: from function to structure. Mol. Pharmacol. 86, 463\u2013478 (2014).","journal-title":"Mol. Pharmacol."},{"key":"9265_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuropharm.2018.07.032","volume":"140","author":"A Belhocine","year":"2018","unstructured":"Belhocine, A. et al. Profiling of orthosteric and allosteric group-III metabotropic glutamate receptor ligands on various G protein-coupled receptors with Tag-lite\u00ae assays. Neuropharmacology 140, 233\u2013245 (2018).","journal-title":"Neuropharmacology"},{"key":"9265_CR45","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1124\/mol.117.111518","volume":"93","author":"SD Hellyer","year":"2018","unstructured":"Hellyer, S. D. et al. Selective\u2019 class C G protein-coupled receptor modulators are neutral or biased mGlu5 allosteric ligands. Mol. Pharmacol. 93, 504\u2013514 (2018).","journal-title":"Mol. Pharmacol."},{"key":"9265_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1523\/JNEUROSCI.1129-13.2014","volume":"34","author":"S Yin","year":"2014","unstructured":"Yin, S. et al. Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS. J. Neurosci. 34, 79\u201394 (2014).","journal-title":"J. Neurosci."},{"key":"9265_CR47","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1111\/febs.15809","volume":"289","author":"MA Rossotti","year":"2022","unstructured":"Rossotti, M. A., B\u00e9langer, K., Henry, K. A. & Tanha, J. Immunogenicity and humanization of single-domain antibodies. FEBS J. 289, 4304\u20134327 (2022).","journal-title":"FEBS J."},{"key":"9265_CR48","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","volume":"78","author":"S Duggan","year":"2018","unstructured":"Duggan, S. Caplacizumab: first global approval. Drugs 78, 1639\u20131642 (2018).","journal-title":"Drugs"},{"key":"9265_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40259-024-00648-3","volume":"38","author":"K Tsumoto","year":"2024","unstructured":"Tsumoto, K. & Takeuchi, T. Next-generation anti-TNF\u03b1 agents: the example of ozoralizumab. BioDrugs 38, 341\u2013351 (2024).","journal-title":"BioDrugs"},{"key":"9265_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41421-021-00357-z","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. SARS-CoV-2 uses metabotropic glutamate receptor subtype 2 as an internalization factor to infect cells. Cell Discov. 7, 119 (2021).","journal-title":"Cell Discov."},{"key":"9265_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fnbeh.2013.00209","volume":"7","author":"D Sargin","year":"2013","unstructured":"Sargin, D. et al. CREB regulates spine density of lateral amygdala neurons: implications for memory allocation. Front. Behav. Neurosci. 7, 209 (2013).","journal-title":"Front. Behav. Neurosci."},{"key":"9265_CR52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0896-6273(00)80958-7","volume":"19","author":"AJ Silva","year":"1997","unstructured":"Silva, A. J. et al. Mutant mice and neuroscience: recommendations concerning genetic background. Neuron 19, 755\u2013759 (1997).","journal-title":"Neuron"},{"key":"9265_CR53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1096\/fj.10-163147","volume":"25","author":"E Doumazane","year":"2011","unstructured":"Doumazane, E. et al. A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors. FASEB J. 25, 66\u201377 (2011).","journal-title":"FASEB J."},{"key":"9265_CR54","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41589-022-01050-2","volume":"18","author":"J Meng","year":"2022","unstructured":"Meng, J. et al. Nanobody-based sensors reveal a high proportion of mGlu heterodimers in the brain. Nat. Chem. Biol. 18, 894\u2013903 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"9265_CR55","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1194\/jlr.D059725","volume":"56","author":"J-P Pais de Barros","year":"2015","unstructured":"Pais de Barros, J.-P. et al. Quantitative lipopolysaccharide analysis using HPLC\/MS\/MS and its combination with the limulus amebocyte lysate assay. J. Lipid Res. 56, 1363\u20131369 (2015).","journal-title":"J. Lipid Res."},{"key":"9265_CR56","doi-asserted-by":"publisher","first-page":"100610","DOI":"10.1016\/j.xops.2024.100610","volume":"5","author":"PP Larsen","year":"2025","unstructured":"Larsen, P. P. et al. Association of lipopolysaccharide-type endotoxins with retinal neurodegeneration: the Alienor study. Ophthalmol. Sci. 5, 100610 (2025).","journal-title":"Ophthalmol. Sci."},{"key":"9265_CR57","unstructured":"Franklin, K. B. J. & Paxinos, G. The Mouse Brain in Stereotaxic Coordinates, Compact\u20143rd Edition (Elsevier, 2008); www.elsevier.com\/books\/the-mouse-brain-in-stereotaxic-coordinates-compact\/franklin\/978-0-12-374244-5."},{"key":"9265_CR58","doi-asserted-by":"publisher","first-page":"7654","DOI":"10.1523\/JNEUROSCI.0091-13.2013","volume":"33","author":"TV Lipina","year":"2013","unstructured":"Lipina, T. V., Zai, C., Hlousek, D., Roder, J. C. & Wong, A. H. C. Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice. J. Neurosci. 33, 7654\u20137666 (2013).","journal-title":"J. Neurosci."},{"key":"9265_CR59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00213-005-2210-x","volume":"179","author":"T Lipina","year":"2005","unstructured":"Lipina, T., Labrie, V., Weiner, I. & Roder, J. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179, 54\u201367 (2005).","journal-title":"Psychopharmacology"},{"key":"9265_CR60","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.physbeh.2005.09.002","volume":"87","author":"R Paylor","year":"2006","unstructured":"Paylor, R., Spencer, C. M., Yuva-Paylor, L. A. & Pieke-Dahl, S. The use of behavioral test batteries, II: effect of test interval. Physiol. Behav. 87, 95\u2013102 (2006).","journal-title":"Physiol. Behav."},{"key":"9265_CR61","doi-asserted-by":"publisher","first-page":"e0199341","DOI":"10.1371\/journal.pone.0199341","volume":"13","author":"Y Chen","year":"2018","unstructured":"Chen, Y. et al. Restoring striatal WAVE-1 improves maze exploration performance of GluN1 knockdown mice. PLoS ONE 13, e0199341 (2018).","journal-title":"PLoS ONE"},{"key":"9265_CR62","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1601-183X.2007.00302.x","volume":"6","author":"G Xie","year":"2007","unstructured":"Xie, G. et al. Forward genetic screen of mouse reveals dominant missense mutation in the P\/Q-type voltage-dependent calcium channel, CACNA1A. Genes Brain Behav. 6, 717\u2013727 (2007).","journal-title":"Genes Brain Behav."},{"key":"9265_CR63","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/0024-3205(81)90697-4","volume":"28","author":"S Amir","year":"1981","unstructured":"Amir, S., Brown, Z. W., Amit, Z. & Ornstein, K. Body pinch induces long lasting cataleptic like immobility in mice: behavioral characterization and the effect of naloxone. Life Sci. 28, 1189\u20131194 (1981).","journal-title":"Life Sci."},{"key":"9265_CR64","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nchembio.2286","volume":"13","author":"P Scholler","year":"2017","unstructured":"Scholler, P. et al. HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat. Chem. Biol. 13, 372\u2013380 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"9265_CR65","doi-asserted-by":"publisher","first-page":"e10605","DOI":"10.15252\/emmm.201910605","volume":"12","author":"C Berthoux","year":"2020","unstructured":"Berthoux, C. et al. Early 5-HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. EMBO Mol. Med. 12, e10605 (2020).","journal-title":"EMBO Mol. Med."},{"key":"9265_CR66","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/nmeth.2738","volume":"10","author":"M Krzywinski","year":"2013","unstructured":"Krzywinski, M. & Altman, N. Power and sample size. Nat. Methods 10, 1139\u20131140 (2013).","journal-title":"Nat. Methods"},{"key":"9265_CR67","doi-asserted-by":"publisher","first-page":"e98856","DOI":"10.1371\/journal.pone.0098856","volume":"9","author":"JA Hirst","year":"2014","unstructured":"Hirst, J. A. et al. The need for randomization in animal trials: an overview of systematic reviews. PLoS ONE 9, e98856 (2014).","journal-title":"PLoS ONE"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09265-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:05:10Z","timestamp":1756911910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09265-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":67,"journal-issue":{"issue":"8079","published-print":{"date-parts":[[2025,9,4]]}},"alternative-id":["9265"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09265-8","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have related patents granted under patent numbers WO2016001417A1 (J.-P.P., P.C. and P.R.), WO2024003389A1 (J.-P.P., P.R., P.C., J.K., M.O., A.R. and C.B.) and WO2024003390A1 (J.-P.P., P.R., L.P., J.K., M.O. and M.T.). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}